ResMed (RMD) Stock Forecast & Price Target

$253.67 -4.40 (-1.71%)

As of 09:43 AM Eastern

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
1

Hold
4

Buy
9

Based on 14 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 1 has given a sell rating, 4 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for RMD.

Consensus Price Target

$259.33
2.25% Upside

According to the 14 analysts' twelve-month price targets for ResMed, the average price target is $259.33. The highest price target for RMD is $290.00, while the lowest price target for RMD is $180.00. The average price target represents a forecasted upside of 2.25% from the current price of $253.62.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

RMD Analyst Ratings Over Time

Type	Current Forecast 7/14/24 to 7/14/25	1 Month Ago 6/14/24 to 6/14/25	3 Months Ago 4/15/24 to 4/15/25	1 Year Ago 7/15/23 to 7/14/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	4 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$259.33	$259.33	$249.73	$202.80
Forecasted Upside	2.25% Upside	4.08% Upside	16.70% Upside	-0.99% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Medical Companies	S&P 500
Consensus Rating Score	2.64	2.80	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	2.04% Upside	8,588.79% Upside	10.53% Upside
News Sentiment Rating	Positive News See Recent RMD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/20/2025	Morgan Stanley 3 of 5 stars	David Bailey Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Overweight ➝ Overweight	$286.00	+16.50%
4/24/2025	KeyCorp 3 of 5 stars	Brett Fishbin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$274.00	+18.04%
4/24/2025	Royal Bank Of Canada 3 of 5 stars	Craig Wong-Pan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Perform ➝ Sector Perform	$247.00 ➝ $255.00	+6.64%
4/24/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Sutcliffe Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$290.00 ➝ $285.00	+19.36%
4/24/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Low Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$286.00 ➝ $290.00	+22.49%
4/24/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Maeder Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$260.00 ➝ $248.00	+5.20%
4/16/2025	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$265.00	+25.12%
3/5/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mathieu Chevrier Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy
3/5/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$250.00 ➝ $240.00	+8.46%
1/31/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
Get the Latest News and Ratings for RMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.
1/16/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Thillainathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
10/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$280.00 ➝ $283.00	+18.39%
9/26/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$240.00 ➝ $270.00	+11.12%
9/24/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/18/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Peer Perform ➝ Underperform	$180.00	-28.25%
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
10/5/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$240.00 ➝ $165.00	+11.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:43 AM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, July 10, 2025. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

The current stock price is around $38.05 billion in market capitalization, indicating a strong position in the medical equipment sector.
ResMed Inc. reported a quarterly earnings per share (EPS) of $2.37, exceeding analysts' expectations, which reflects strong financial performance and potential for growth.
The company has a solid net margin of 26.15%, suggesting effective cost management and profitability, which can lead to higher returns for investors.
With a return on equity of 25.67%, ResMed Inc. demonstrates efficient use of shareholders' equity to generate profits, making it an attractive investment.
The firm has a low debt-to-equity ratio of 0.12, indicating a conservative approach to leverage, which reduces financial risk for investors.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

The price-to-earnings ratio of 29.12 may suggest that the stock is overvalued compared to its earnings, which could deter value-focused investors.
Despite a strong performance, the dividend yield is relatively low at 0.83%, which may not attract income-focused investors looking for higher returns from dividends.
The company's beta of 0.77 indicates lower volatility compared to the market, which might not appeal to investors seeking high-risk, high-reward opportunities.
While revenue growth is positive, it is essential to monitor market conditions that could impact future growth, especially in the competitive healthcare sector.
ResMed Inc. operates in a highly regulated industry, which can pose risks related to compliance and operational costs that may affect profitability.

RMD Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $259.33, with a high forecast of $290.00 and a low forecast of $180.00.
: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There is currently 1 sell rating, 4 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.
: According to analysts, ResMed's stock has a predicted upside of 2.25% based on their 12-month stock forecasts.
: ResMed has been rated by research analysts at JPMorgan Chase & Co., KeyCorp, Mizuho, Morgan Stanley, Piper Sandler, Royal Bank Of Canada, and UBS Group in the past 90 days.
: Analysts like ResMed less than other "medical" companies. The consensus rating score for ResMed is 2.64 while the average consensus rating score for "medical" companies is 2.80. Learn more on how RMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:RMD) was last updated on 7/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Stock Forecast & Price Target